甲磺酸萘莫司他在ICU床旁CRRT患者抗凝治疗有效性及安全性的研究

打开文本图片集

Study on the Effect and Safetyof in the Anticoagulation Treatment of Patients with CRRTat Bedside of ICU/WANGFei， WANG Jiawei，RAO Zonglin，LOU Wenshui，WANG Xiaoxiao，XU Zhongbo，XIA Wang，LIU Qunyan.//Medical Innovation of China，2025， 22（19）： 014-018

[Abstract] Objective： To investigate the effect and safety of Nafamostat Mesylate in anticoagulant therapy for patients undergoing bedside continuous renal replacement therapy （CRRT） inthe ICU.Method： A total of 80 patients withbedside CRRT in the ICUofin Shangrao People's Hospital from June 2022 to June 2O24 were divided into control group 40O cases and observation group 4O cases by the random number table method. The control group was anticoagulated with Sodium Citrate，the observation group wasanticoagulated with Nafamostat Mesylate.The coagulationindexes （APTT，TT），respiratoryandcirculatoryindexes（MAP，HRandSpO2），liverandrenalfunction indexes （ALT，ASTandScr）and platelet activation indexes[plateletmembrane glycoprotein IIb（CD41）andP-selectin （CD62p）] at diffrent time，adverseevent rates of two groups were compared.Result： Before medication，there were no statisticallsignificantdiferences incoagulationindicators，respiratoryand ciculatoryindicators，liverandrenal function indicators，and platelet activation indicators between the two groups （ P >0.05）. The coagulation indexes and platelet activation indexes of observation group at 3O minutes and 2，4，8，12，and24 hours after medication were lower than those of control group，the differences were statistically significant （ P <0.05）. There were no statistically significant diferences intherespiratoryandcirculatory indicatorsat3Ominutes and2，4，8，12，and24 hoursafter medication and the liver and renal function indicators at 24 hours after medication between the two groups （ P>0.05 ） The incidence ofadverse events inthe observation group was lower than thatin thecontrol group，the diference was statistically significant P <0.05）.Conclusion： Nafamostat Mesylate has a good anticoagulation effect in patients with bedside CRRT in the ICU，and its safety is relatively high.

[Key words] Nafamostat Mesylate ICU CRRT Anticoagulation

First-author'saddress：Departmentof Critical Care Medicine，Shangrao People's Hospital，Shangrao 334000， China

doi：10.3969/j.issn.1674-4985.2025.19.004

ICU患者因多方面病因及创伤存在，可导致多系统器官功能衰竭，机体循环较差，炎症损伤突出，因此需采用连续性肾脏替代治疗（CRRT）进行治疗，而抗凝治疗作为本类治疗的重要部分，其关系到CRRT实施的效果，抗凝不足及抗凝过度均不利于治疗的顺利实施，也是与多类不良事件的发生密切相关的方面[1-2]。（剩余5337字）